OMNIAB, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
OMNIAB, INC. (OABI) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$1.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-06
- OMNIAB, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $977.00K, a 18.38% decline year-over-year.
- OMNIAB, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$2.52M.
- OMNIAB, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $1.26M, a 62.37% increase year-over-year.
- OMNIAB, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $280.00K, a 30.35% decline year-over-year.
- OMNIAB, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$231.00K.
- OMNIAB, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$2.41M, a 361.96% decline from fiscal 2023.
- OMNIAB, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $920.00K, a 93.89% decline from fiscal 2022.
- OMNIAB, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $15.07M, a 895.90% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $977.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.54M 10-Q · filed 2026-08-06 | -$285.00K derived: sum of 3 quarters · filed 2026-08-06 | -$5.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$2.52M 10-Q · filed 2026-05-07 | -$1.26M derived: sum of 2 quarters · filed 2026-05-07 | -$982.00K derived: sum of 3 quarters · filed 2026-05-07 | $215.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $1.54M derived: sum of 2 quarters · filed 2026-03-04 | $2.74M derived: sum of 3 quarters · filed 2026-08-06 | -$231.00K 10-K · filed 2026-03-04 | ||
| 2025-09-30 | $280.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.48M derived: sum of 2 quarters · filed 2026-08-06 | -$1.49M 10-Q · filed 2025-11-04 | -$715.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.77M 10-Q · filed 2026-08-06 | -$995.00K derived: sum of 3 quarters · filed 2026-08-06 | -$593.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$2.97M 10-Q · filed 2026-05-07 | -$2.19M derived: sum of 2 quarters · filed 2026-05-07 | -$1.79M derived: sum of 3 quarters · filed 2026-05-07 | -$1.95M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $776.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $1.18M derived: sum of 2 quarters · filed 2026-03-04 | $1.01M derived: sum of 3 quarters · filed 2026-03-04 | -$2.41M 10-K · filed 2026-03-04 | ||
| 2024-09-30 | $402.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $238.00K derived: sum of 2 quarters · filed 2025-11-04 | -$3.19M 10-Q · filed 2025-11-04 | -$3.71M derived: sum of 4 quarters · filed 2025-11-04 | ||
| 2024-06-30 | -$164.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$3.59M 10-Q · filed 2025-08-06 | -$4.11M derived: sum of 3 quarters · filed 2025-08-06 | -$2.03M derived: sum of 4 quarters · filed 2025-08-06 | ||
| 2024-03-31 | -$3.42M 10-Q · filed 2025-05-08 | -$3.95M derived: sum of 2 quarters · filed 2025-05-08 | -$1.87M derived: sum of 3 quarters · filed 2025-05-08 | -$761.00K derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | -$526.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.55M derived: sum of 2 quarters · filed 2025-03-18 | $2.66M derived: sum of 3 quarters · filed 2025-03-18 | $920.00K 10-K · filed 2025-03-18 | $936.00K 10-K · filed 2024-03-25 | |
| 2023-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.19M derived: sum of 2 quarters · filed 2024-11-12 | $1.45M 10-Q · filed 2024-11-12 | $16.08M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$635.00K 10-Q · filed 2024-08-08 | -$162.00K 10-Q · filed 2023-08-10 | $14.00M derived: sum of 3 quarters · filed 2024-08-08 | $16.18M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$1.74M 10-Q · filed 2024-05-09 | $12.89M derived: sum of 2 quarters · filed 2024-05-09 | $15.07M derived: sum of 3 quarters · filed 2024-05-09 | $15.12M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $14.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $16.82M derived: sum of 2 quarters · filed 2024-03-25 | $16.86M derived: sum of 3 quarters · filed 2024-03-25 | $15.07M 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.23M derived: sum of 2 quarters · filed 2023-11-09 | $432.00K 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$1.75M 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | -$1.79M 10-Q · filed 2023-05-11 | |||||
| 2021-12-31 | $1.51M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |